LCB-39 / LigaChem Biosci - LARVOL DELTA

LCB39, a novel systemically deliverable STING agonist with strong preclinical activity and tolerability (AACR 2025) - "LCB39 is a highly differentiated potent STING agonist with a safety profile, which suggested that LCB39 may have the potential to be the best-in-class STING agonist to treat solid cancers. LCB39 plans to enter first-in-human clinical study in early 2026."

Preclinical • Oncology • Solid Tumor • CD8

Ligachem Bio Strengthens Global Position with Preclinical Results of LCB39 and ADC Candidates [Google translation] (Nate) - "Biotechnology company Ligachem Biosciences will present the results of a total of five preclinical studies, including the next-generation immunotherapy STING agonist 'LCB39', at the '2025 American Association for Cancer Research (AACR)' held in Chicago, USA from the 25th to the 30th....This presentation includes oral and poster presentations on candidates such as LCB39, an immune-oncology drug candidate independently developed by Ligachembio, as well as SOT106 (LRRC15 ADC) and IKS04 (CA242 ADC), which were derived through the transfer of antibody-drug conjugate (ADC) platform technology."

Preclinical • Oncology

LCB39, a novel systemically deliverable STING agonist presents robust anti-tumor activity with enhanced tumor-targeting and tolerability in preclinical study (SITC 2024) - "Conclusions LCB39 is a highly differentiated potent STING agonist with a safety profile, which suggested that LCB39 may have the potential to be the best-in-class STING agonist to treat solid cancers. LCB39 plans to enter first-in-human clinical study in early 2026."

Preclinical • Oncology • Solid Tumor • CD34 • CD8 • GLI2 • STING

Ligachem Bio announces non-clinical data of immunotherapy 'LCB39' at SITC [Google translation] (HIT News) - "According to this announcement, even when low doses of LCB39 were administered, a tumor growth inhibition rate of over 80% and complete remission were confirmed in the existing immune checkpoint inhibitor-refractory cancer cell (cold tumor) model and orthotopic transplantation model. In addition, LCB39 administration activated innate immune cells such as dendritic cells, macrophages, and CD8 T cells within actual cancer tissues."

Preclinical • Oncology • Solid Tumor